Research programme: BACE1 protein inhibitors - Astellas Pharma/CoMentis
Alternative Names: BACE inhibitors - CoMentis; Disease modifying Alzheimer's disease therapy - CoMentis; OM 991; OM 992Latest Information Update: 04 Nov 2017
At a glance
- Originator CoMentis
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 16 Oct 2014 Astellas Pharma exercises option to terminate its collaboration agreement with CoMentis
- 25 Apr 2008 Astellas Pharma and CoMentis have entered into an exclusive worldwide collaboration agreement to develop and commercialise products from CoMentis' β-secretase inhibitor programme